Targeting serine metabolism, particularly via PHGDH inhibition, not only suppresses tumor growth through nutrient deprivation but also crucially blocks compensatory pro-metastatic adaptations mediated by the SSP that can be triggered by other therapies, such as chemotherapy. The gene discussed is PHGDH; the disease is neoplasm.